Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2019 08:16 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference

Pittsburgh, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
September 04, 2019 08:04 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Give Webcast Presentation at 3rd Annual Janney Healthcare Conference on September 9, 2019

Pittsburgh, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
July 24, 2019 09:27 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China

Pittsburgh, July 24, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
July 09, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts

PITTSBURGH, July 09, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
June 05, 2019 08:07 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Appoints Anthony O. Caggiano M.D., Ph.D. to the Position of Chief Medical Officer

Pittsburgh, June 05, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., today announced that Anthony O. Caggiano, M.D., Ph.D. has joined the Company as chief medical officer (CMO). Cognition...
April 05, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens

Pittsburgh, April 05, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
March 26, 2019 09:51 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors

Pittsburgh, March 26, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
February 21, 2019 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives European Patent Covering its Alzheimer's Disease Candidate, Elayta™

Pittsburgh, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
February 19, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™

Pittsburgh, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
November 27, 2018 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease

Pittsburgh, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...